Australia markets closed

uniQure N.V. (QURE)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
4.6700-0.0400 (-0.85%)
At close: 04:00PM EDT
4.6700 0.00 (0.00%)
After hours: 04:17PM EDT

uniQure N.V.

Paasheuvelweg 25
Amsterdam 1105 BP
Netherlands
31 20 240 6000
https://www.uniqure.com

Sector(s)Healthcare
IndustryBiotechnology
Full-time employees480

Key executives

NameTitlePayExercisedYear born
Mr. Matthew Craig KapustaCEO & Executive Director1.16MN/A1972
Mr. Christian KlemtCFO, Principal Financial Officer & GM of Amsterdam Site566.36kN/A1973
Mr. Pierre CalozChief Operating Officer951.1kN/A1972
Prof. Hugo KatusChairman of Scientific Advisory Board and Managing Director of UniQure-GermanyN/AN/AN/A
Mr. Richard Porter Ph.D.Chief Business & Scientific OfficerN/AN/AN/A
Dr. Jeannette Potts J.D., Ph.D.Chief Legal & Compliance OfficerN/AN/A1962
Dr. Tamara Tugal Ph.D., MBABusiness Development DirectorN/AN/AN/A
Ms. Carla PoulsonInterim Chief People and Culture OfficerN/AN/AN/A
Ms. Maria E. CantorChief Corporate Affairs Officer491.12kN/A1968
Dr. Amin Abujoub Ph.D.Chief Quality OfficerN/AN/AN/A
Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease. In addition, it is developing AMT-162, which is in preclinical trial for the treatment of superoxide dismutase 1- amyotrophic lateral sclerosis; AMT-260 that is in preclinical trial to treat temporal lobe epilepsy; AMT-191, which is in preclinical trial for the treatment of fabry disease; AMT-161 that is in preclinical trial to treat amyotrophic lateral sclerosis caused by mutations; AMT-240, which is in preclinical trial to for the treatment of autosomal dominant Alzheimer's disease; and AMT-210 that is in preclinical trial to treat Parkinson's disease. The company was founded in 1998 and is headquartered in Amsterdam, the Netherlands.

Corporate governance

uniQure N.V.’s ISS governance QualityScore as of 1 April 2024 is 2. The pillar scores are Audit: 5; Board: 3; Shareholder rights: 1; Compensation: 5.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.